iSERA Lifesciences to increase authorized capital to ₹25 Cr
iSERA Lifesciences Limited (formerly Covidh Technologies Limited) announced the revised outcome of its Board Meeting held on April 21, 2026. The Board approved increasing the Authorised Share Capital from ₹11 Crore to ₹25 Crore, subject to shareholder approval. Additionally, the Board approved the adoption of new Memorandum and Articles of Association to align with the Companies Act, 2013, also subject to shareholder approval via special resolution. The limit for investments, loans, or guarantees under Section 186 of the Companies Act, 2013, was enhanced to ₹1,000 Crore, pending shareholder approval. The Board also took on record and approved valuation reports for a proposed preferential issue of equity shares on a Share Swap basis.
Key Highlights
- Authorized share capital increased from ₹11 Cr to ₹25 Cr.
- New Memorandum and Articles of Association adopted.
- Investment/loan limit under Section 186 enhanced to ₹1,000 Cr.
- Valuation reports for preferential share swap issue approved.
- All approvals are subject to shareholder consent via postal ballot/e-voting.
Price Impact
More from COVIDH